Esperion Therapeutics | ESPR - Operating Profit


Esperion Therapeutics reported $85.23M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amarin USD -2.26M 564K Dec/2025
Amgen USD 3.83B 130M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cipla INR 6.14B 3.63B Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Geron USD -236K 10.55M Mar/2026
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -1.39B 531M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Sanofi EUR 1.94B 239M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024